Trifluorinated Pyrimidine-Based A Antagonists: Optimization and Evidence of Stereospecific Recognition.

Ana Mallo-Abreu, María Majellaro, Willem Jespers, Jhonny Azuaje, Olga Caamaño, Xerardo García-Mera, José M Brea, María I Loza, Hugo Gutiérrez-de-Terán, Eddy Sotelo

Journal: Journal of medicinal chemistry 2020;62(20):9315-9330

PMID: 31557025

Abstract

We report the identification of two subsets of fluorinated nonxanthine A adenosine receptor antagonists. The novel derivatives explore the effect of fluorination at different positions of two pyrimidine-based scaffolds. The most interesting ligands combine excellent hA affinity ( < 15 nM) and remarkable subtype selectivity. The results of functional cAMP experiments confirmed the antagonistic behavior of representative ligands. The compounds were designed on the basis of previous molecular models of the stereoselective binding of the parent scaffolds to the hA receptor, and we herein provide refinement of such models with the fluorinated compounds, which allows the explanation of the spurious effects of the fluorination at the different positions explored. These models are importantly confirmed by a synergistic study combining chiral HPLC, circular dichroism, diastereoselective synthesis, molecular modeling, and X-ray crystallography, providing experimental evidence toward the stereospecific interaction between optimized trifluorinated stereoisomers and the hA receptor.

Address: Department of Cell and Molecular Biology , Uppsala University , Uppsala SE-75124 , Sweden.; Centro Singular de Investigación en Medicina Molecular y Enfermedades Crónicas (CIMUS) , Universidade de Santiago de Compostela , 15782 Santiago de Compostela , Spain.

Link outs

Free resources

Subscription / membership required

Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.